← Back to Search

Hormone Therapy

oxytocin nasal spray for Obesity

Phase 2
Waitlist Available
Led By Elizabeth A Lawson, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 8 weeks
Awards & highlights

Study Summary

This trial is testing whether the hormone oxytocin can help obese adults lose weight.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Difference in Weight Loss Between Oxytocin and Placebo 8 Weeks After Baseline
Secondary outcome measures
Change in Fat Depots After 8 Weeks of Oxytocin Versus Placebo
Change in Resting Energy Expenditure After 8 Weeks of Oxytocin Versus Placebo
Difference in Caloric Intake After 6 Weeks of Oxytocin Versus Placebo

Side effects data

From 2022 Phase 2 trial • 61 Patients • NCT03043053
19%
Nasal discomfort
16%
Headache
13%
Blood glucose increased
6%
Uterine pain
6%
Contusion
6%
Wound complication
6%
Liver function test increased
6%
Upper respiratory tract infection
3%
Dyspnea
3%
Rhinorrhea
3%
Dysuria
3%
Epistaxis
3%
Presyncope
3%
Diarrhea
3%
Polyuria
3%
Sinus congestion
3%
Carpal tunnel syndrome
3%
Parasthesia
3%
Skin ulcer
3%
Gastrointestinal viral infection
3%
Blood potassium increased
3%
Constipation
3%
Nausea
3%
Oedema
3%
Hypertension
3%
Anxiety
3%
Acne
3%
Pain in extremity
3%
Ligament sprain
3%
Abdominal discomfort
3%
Hemorrhoids
3%
Gastroesophageal reflux disease
3%
Thirst
3%
Nasal congestion
3%
COVID-19
3%
Arthralgia
3%
Rash
3%
Electrocardiogram QT prolonged
3%
Back pain
3%
Dysphoria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Oxytocin
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: oxytocinExperimental Treatment1 Intervention
oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
Group II: placeboPlacebo Group1 Intervention
placebo nasal spray (4 times per day for 8 weeks)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
oxytocin nasal spray
2017
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,925 Previous Clinical Trials
13,197,843 Total Patients Enrolled
70 Trials studying Obesity
290,830 Patients Enrolled for Obesity
Elizabeth A Lawson, MDPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
86 Total Patients Enrolled
1 Trials studying Obesity
61 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
The Effects of Oxytocin in Obese Adults
Elizabeth Austen Lawson 2017. "The Effects of Oxytocin in Obese Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03043053.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top